Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.
Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.
J Vasc Surg. 2021 Jul;74(1):13-19. doi: 10.1016/j.jvs.2020.11.040. Epub 2020 Dec 16.
Renal dysfunction can be a prohibitive risk for open repair of complex thoracoabdominal aortic aneurysms (TAAAs) and pararenal aortic aneurysms (PRAAs). However, the effect of renal dysfunction from fenestrated and branched endovascular aneurysm repair (FB-EVAR) on outcomes is poorly defined. Our objective was to review the association of renal function on patient survival after FB-EVAR.
The present study reviewed the clinical data of consecutive patients enrolled in a prospective nonrandomized study to investigate FB-EVAR for PRAAs and TAAAs at a single institution with 1 year of follow-up (2013-2017). The patients were categorized by preoperative chronic kidney disease (CKD) classification, and the early- and long-term mortality was assessed.
During the study period, 231 patients had undergone FB-EVAR for 80 PRAAs, 89 type I-III TAAAs, and 62 type IV TAAAs. The mean age was 74.6 ± 6.7 years, and 71% were men. Of the 231 patients, 126 had had CKD stage 1-2, 96 CKD stage 3, and 9 CKD stage 4-5 (all with baseline creatinine >2.0 mg/dL). Patients with CKD stage 4-5 had demographic data similar to those with normal renal function but had had slightly larger aneurysms (6.5 vs 7 cm; P = .15). The 30-day mortality was 0.5% (n = 1) for those with CKD 1-3 vs 0% for those with CKD 4-5 (P = .73). The 1- and 3-year survival analysis showed no major hazards (95% vs 88% and 84% vs 75%, respectively; log-rank P = .98) between the CKD 1-3 and CKD 4-5 groups. The median follow-up period was 2.6 years (interquartile range, 1.5-3.7 years). Two patients with CKD 4-5 had died during the follow-up period.
Although a small sample size for evaluation, selected patients with CKD 4-5 might have similar short- and long-term mortality compared with those with normal to moderate renal dysfunction after FB-EVAR. Although a major contraindication for open repair, renal dysfunction might not be as prohibitive for endovascular repair in well-selected patients.
肾功能障碍可能是开放修复复杂胸腹主动脉瘤(TAAAs)和肾周主动脉瘤(PRAAs)的一个显著风险因素。然而,经腔内开窗和分支血管重建术(FB-EVAR)导致的肾功能障碍对结局的影响尚未明确。我们的目的是评估 FB-EVAR 后肾功能对患者生存的影响。
本研究回顾了单中心前瞻性非随机研究中连续入组的患者的临床数据,该研究旨在调查 FB-EVAR 治疗 PRAAs 和 TAAAs 的效果,随访时间为 1 年(2013-2017 年)。根据术前慢性肾脏病(CKD)分级对患者进行分类,并评估早期和长期死亡率。
在研究期间,231 例患者接受 FB-EVAR 治疗,其中 80 例 PRAAs,89 例 I-III 型 TAAAs 和 62 例 IV 型 TAAAs。患者平均年龄为 74.6±6.7 岁,71%为男性。231 例患者中,126 例 CKD 1-2 期,96 例 CKD 3 期,9 例 CKD 4-5 期(所有患者基线肌酐>2.0mg/dL)。CKD 4-5 期患者的人口统计学数据与肾功能正常患者相似,但瘤体稍大(6.5 对 7cm;P=0.15)。CKD 1-3 期患者 30 天死亡率为 0.5%(n=1),而 CKD 4-5 期患者为 0%(P=0.73)。1 年和 3 年生存分析显示,CKD 1-3 期和 CKD 4-5 期两组之间无主要危险(95%vs88%和 84%vs75%;log-rank P=0.98)。中位随访时间为 2.6 年(四分位间距,1.5-3.7 年)。2 例 CKD 4-5 期患者在随访期间死亡。
尽管评估样本量较小,但与 FB-EVAR 后肾功能正常或中度障碍的患者相比,选择的 CKD 4-5 期患者的短期和长期死亡率可能相似。尽管肾功能障碍是开放修复的主要禁忌证,但在选择合适的患者中,经腔内修复术可能并非如此。